Xenetic Biosciences (XBIO) Equity Average (2023 - 2025)
Xenetic Biosciences (XBIO) has disclosed Equity Average for 5 consecutive years, with $4.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 41.95% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Sep 2025, down 41.95%, and an annual FY2024 reading of $7.9 million, changed N/A over the prior year.
- Equity Average was $4.2 million for Q3 2025 at Xenetic Biosciences, down from $4.8 million in the prior quarter.
- Across five years, Equity Average topped out at $12.4 million in Q2 2023 and bottomed at $4.2 million in Q3 2025.
- Average Equity Average over 3 years is $7.8 million, with a median of $7.2 million recorded in 2024.
- The sharpest move saw Equity Average soared 46.67% in 2024, then tumbled 41.95% in 2025.
- Year by year, Equity Average stood at $10.3 million in 2023, then tumbled by 36.95% to $6.5 million in 2024, then crashed by 35.55% to $4.2 million in 2025.
- Business Quant data shows Equity Average for XBIO at $4.2 million in Q3 2025, $4.8 million in Q2 2025, and $5.6 million in Q1 2025.